An open-randomized clinical trial of selegiline in amyotrophic lateral sclerosis

Letizia Mazzini, Daniela Testa, Carla Balzarini, Gabriele Mora

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Based on the hypothesis that free radicals play a general role in the neurodegenerative process in motor neuron disease, we tested selegiline in a group of patients affected by amyotrophic lateral sclerosis (ALS) to examine whether it might modify the progression of the disease. Patients were admitted if they were 25-80 years old and had a confirmed diagnosis of ALS with symptoms lasting no longer than 24 months. Patients with familial ALS, pure progressive bulbar palsy, primary lateral sclerosis or progressive muscle atrophy were excluded; a total of 111 patients were recruited. Fifty-three patients were randomly assigned to receive the drug (selegiline 10 mg/day orally for 6 months) and the remaining 58 were considered ALS controls. Mortality was similar in the two groups (4 and 5 patients respectively), though the difference was not statistically significant. Among the survivors, mean MRC and Norris disability scores and forced vital capacity were fairly similar in the two groups at all times and no statistically significant difference between treated and untreated patients was found. The results did not change when the data were related to age, duration and characteristics of onset of the disease. The rate of progression was significantly more rapid in patients with bulbar symptoms in both groups. Our data do not show any significant effect of selegiline in modifying the progression of ALS.

Original languageEnglish
Pages (from-to)223-227
Number of pages5
JournalJournal of Neurology
Volume241
Issue number4
DOIs
Publication statusPublished - Apr 1994

Fingerprint

Selegiline
Amyotrophic Lateral Sclerosis
Randomized Controlled Trials
Motor Neuron Disease
Progressive Bulbar Palsy
Muscular Atrophy
Vital Capacity
Free Radicals
Survivors
Disease Progression
Mortality

Keywords

  • Amyotrophic lateral sclerosis
  • Free radicals
  • Selegiline

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

An open-randomized clinical trial of selegiline in amyotrophic lateral sclerosis. / Mazzini, Letizia; Testa, Daniela; Balzarini, Carla; Mora, Gabriele.

In: Journal of Neurology, Vol. 241, No. 4, 04.1994, p. 223-227.

Research output: Contribution to journalArticle

Mazzini, Letizia ; Testa, Daniela ; Balzarini, Carla ; Mora, Gabriele. / An open-randomized clinical trial of selegiline in amyotrophic lateral sclerosis. In: Journal of Neurology. 1994 ; Vol. 241, No. 4. pp. 223-227.
@article{96bc43ee4a24464c9d34a0574eca3bb6,
title = "An open-randomized clinical trial of selegiline in amyotrophic lateral sclerosis",
abstract = "Based on the hypothesis that free radicals play a general role in the neurodegenerative process in motor neuron disease, we tested selegiline in a group of patients affected by amyotrophic lateral sclerosis (ALS) to examine whether it might modify the progression of the disease. Patients were admitted if they were 25-80 years old and had a confirmed diagnosis of ALS with symptoms lasting no longer than 24 months. Patients with familial ALS, pure progressive bulbar palsy, primary lateral sclerosis or progressive muscle atrophy were excluded; a total of 111 patients were recruited. Fifty-three patients were randomly assigned to receive the drug (selegiline 10 mg/day orally for 6 months) and the remaining 58 were considered ALS controls. Mortality was similar in the two groups (4 and 5 patients respectively), though the difference was not statistically significant. Among the survivors, mean MRC and Norris disability scores and forced vital capacity were fairly similar in the two groups at all times and no statistically significant difference between treated and untreated patients was found. The results did not change when the data were related to age, duration and characteristics of onset of the disease. The rate of progression was significantly more rapid in patients with bulbar symptoms in both groups. Our data do not show any significant effect of selegiline in modifying the progression of ALS.",
keywords = "Amyotrophic lateral sclerosis, Free radicals, Selegiline",
author = "Letizia Mazzini and Daniela Testa and Carla Balzarini and Gabriele Mora",
year = "1994",
month = "4",
doi = "10.1007/BF00863772",
language = "English",
volume = "241",
pages = "223--227",
journal = "Journal of Neurology",
issn = "0340-5354",
publisher = "Dr. Dietrich Steinkopff Verlag GmbH and Co. KG",
number = "4",

}

TY - JOUR

T1 - An open-randomized clinical trial of selegiline in amyotrophic lateral sclerosis

AU - Mazzini, Letizia

AU - Testa, Daniela

AU - Balzarini, Carla

AU - Mora, Gabriele

PY - 1994/4

Y1 - 1994/4

N2 - Based on the hypothesis that free radicals play a general role in the neurodegenerative process in motor neuron disease, we tested selegiline in a group of patients affected by amyotrophic lateral sclerosis (ALS) to examine whether it might modify the progression of the disease. Patients were admitted if they were 25-80 years old and had a confirmed diagnosis of ALS with symptoms lasting no longer than 24 months. Patients with familial ALS, pure progressive bulbar palsy, primary lateral sclerosis or progressive muscle atrophy were excluded; a total of 111 patients were recruited. Fifty-three patients were randomly assigned to receive the drug (selegiline 10 mg/day orally for 6 months) and the remaining 58 were considered ALS controls. Mortality was similar in the two groups (4 and 5 patients respectively), though the difference was not statistically significant. Among the survivors, mean MRC and Norris disability scores and forced vital capacity were fairly similar in the two groups at all times and no statistically significant difference between treated and untreated patients was found. The results did not change when the data were related to age, duration and characteristics of onset of the disease. The rate of progression was significantly more rapid in patients with bulbar symptoms in both groups. Our data do not show any significant effect of selegiline in modifying the progression of ALS.

AB - Based on the hypothesis that free radicals play a general role in the neurodegenerative process in motor neuron disease, we tested selegiline in a group of patients affected by amyotrophic lateral sclerosis (ALS) to examine whether it might modify the progression of the disease. Patients were admitted if they were 25-80 years old and had a confirmed diagnosis of ALS with symptoms lasting no longer than 24 months. Patients with familial ALS, pure progressive bulbar palsy, primary lateral sclerosis or progressive muscle atrophy were excluded; a total of 111 patients were recruited. Fifty-three patients were randomly assigned to receive the drug (selegiline 10 mg/day orally for 6 months) and the remaining 58 were considered ALS controls. Mortality was similar in the two groups (4 and 5 patients respectively), though the difference was not statistically significant. Among the survivors, mean MRC and Norris disability scores and forced vital capacity were fairly similar in the two groups at all times and no statistically significant difference between treated and untreated patients was found. The results did not change when the data were related to age, duration and characteristics of onset of the disease. The rate of progression was significantly more rapid in patients with bulbar symptoms in both groups. Our data do not show any significant effect of selegiline in modifying the progression of ALS.

KW - Amyotrophic lateral sclerosis

KW - Free radicals

KW - Selegiline

UR - http://www.scopus.com/inward/record.url?scp=0028347114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028347114&partnerID=8YFLogxK

U2 - 10.1007/BF00863772

DO - 10.1007/BF00863772

M3 - Article

C2 - 8195821

AN - SCOPUS:0028347114

VL - 241

SP - 223

EP - 227

JO - Journal of Neurology

JF - Journal of Neurology

SN - 0340-5354

IS - 4

ER -